scPharmaceuticals Inc

Finanzas de scPharmaceuticals Inc (SCPH)

$5.670

0.000 (0.00%)Al cierre

Rentabilidad y márgenes de SCPH

Evaluating the bottom line, scPharmaceuticals Inc maintains a gross margin of 68.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -89.11%, while the net margin is -112.36%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SCPH converts its operational activities into shareholder value.

Comparativa sectorial de SCPH

In the context of the broader market, SCPH competes directly with industry leaders such as TKNO and OMER. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SCPH's gross margin of 68.76% stands against TKNO's 37.73% and OMER's 97.20%. Such benchmarking helps identify whether scPharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2025Q2
YoY:
+99.17%
16.04M
Total Revenue
FY2025Q2
YoY:
-0.95%
-14.29M
Operating Profit
FY2025Q2
YoY:
+5.47%
-18.02M
Net Income after Tax
FY2025Q2
YoY:
-22.73%
-0.34
EPS - Diluted
FY2024Q4
YoY:
+0.02%
-15.20M
Free Cash Flow
FY2025Q2
YoY:
-3.75%
68.76
Gross Profit Margin - %
FY2024Q4
YoY:
-55.47%
-194.21
FCF Margin - %
FY2025Q2
YoY:
-47.05%
-112.36
Net Margin - %

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis